Targeting IGF1R/INSR pathway with approved ALK inhibitors inhibits AKT signaling and overcomes proteasome inhibitor resistance in multiple myeloma

被引：0
|
作者：
Besse, Andrej
Totu, Tiberiu
Kraus, Marianne
Janssen, Anthonius P.
Veprkova, Jana
Lopez, Max Mendez
Slaby, Ondrej
Buljan, Marija
van der Stelt, Mario
Driessen, Christoph
Besse, Lenka
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7191
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7191
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma
    Mendez-Lopez, Max Alberto
    Besse, Andrej
    Totu, Tiberiu
    Kraus, Marianne
    Janssen, Anthonius P. A.
    Buljan, Marija
    Van der Stelt, Mario
    Besse, Lenka
    Driessen, Christoph
    BLOOD, 2023, 142
  • [2] InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
    Ma, Yufang
    Tang, Nan
    Thompson, Reid C.
    Mobley, Bret C.
    Clark, Steven W.
    Sarkaria, Jann N.
    Wang, Jialiang
    CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1767 - 1776
  • [3] Targeting Redox Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma
    Dolloff, Nathan G.
    Reyes, Leticia
    Smith, Brittany
    Langenheim, John Fairbanks
    Manevich, Yefim
    BLOOD, 2015, 126 (23)
  • [4] Combined inhibition of IGF1R and EGFR signaling overcomes the resistance to 3rd-generation EGFR kinase inhibitors caused by IGF1R activation
    Lee, J. C.
    Park, S.
    Rho, J. K.
    Choi, Y. J.
    Choi, C. M.
    Park, J. H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S1 - S1
  • [5] Targeting the IGF1R signaling pathway inhibits cell growth and dissemination in BCOR mutant retinoblastoma
    Lee, Su-Chan
    Alaali, Lujain
    Eberhart, Charles G.
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Approved ALK-inhibitors induce cytotoxicity in multiple myeloma by targeting the ER-resident kinase LTK and overcome resistance to proteasome inhibitors
    Besse, A.
    Kraus, M.
    Schjesvold, F. H.
    Munthe, L. A.
    Farhan, H.
    Besse, L.
    Driessen, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 99 - 99
  • [7] Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors
    Loganathan, Sudan N.
    Tang, Nan
    Holler, Albert E.
    Wang, Nenghui
    Wang, Jialiang
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (05) : 929 - 936
  • [8] GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL
    Shi, Wenyu
    Li, Jian-Yong
    BLOOD, 2019, 134
  • [9] Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R
    Qi, Wei-liang
    Li, Hui-yu
    Wang, Yi
    Xu, Lan
    Deng, Jie-ting
    Zhang, Xi
    Wang, Yu-xiang
    Meng, Ling-hua
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (05) : 1083 - 1094
  • [10] Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma
    Han, Zhannan
    Yan, Zhibo
    Ma, Zhehan
    Wang, Yihui
    Beus, Maja
    Lu, Junqi
    Weidenhammer, Loren B.
    Lakhani, Kiran
    Lee, Jingyun
    Civils, John D.
    Furdui, Cristina M.
    Liu, Liang
    Wu, Jian
    Kang, Yubin
    Bieberich, Erhard
    Boise, Lawrence H.
    Nikiforov, Mikhail A.
    LEUKEMIA, 2025, 39 (03) : 720 - 733
12345